Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028409 | 0.82 | CA1 (0.69) | KMT2AMEN1NPC1RAB9ACA1 | |
| SCHEMBL3006426 | 0.82 | RAB9A (0.71) | KMT2AMEN1NPC1RAB9ACA1 | |
| SCHEMBL2183629 | 0.81 | NPC1 (0.71) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL6794968 | 0.80 | L3MBTL1 (0.62) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL6491441 | 0.80 | CA1 (0.71) | KMT2AMEN1NPC1RAB9ACA1 | |
| SCHEMBL10576461 | 0.80 | CA1 (0.67) | NPC1RAB9ACA1CA2CA5A | |
| SCHEMBL3453018 | 0.80 | CA1 (0.67) | KMT2AMEN1NPC1RAB9ACA1 | |
| SCHEMBL18546011 | 0.80 | CA1 (0.66) | NPC1RAB9ACA1CA2CA5A | |
| SCHEMBL29765433 | 0.79 | CA1 (0.65) | KMT2AMEN1NPC1RAB9ACA1 | |
| SCHEMBL27841700 | 0.79 | MEN1 (0.74) | KMT2AMEN1NPC1RAB9ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224163-B1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| CN-1478077-A | Benzamide compounds as APO B secretion inhibitors | ����ҩƷ��ҵ��ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-6548522-B1 | N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1224163-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001027070-A1 | USE OF CARBONYLAMINO DERIVATIVES AGAINST CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | KMT2A 2457/4885MEN1 2426/4885NPC1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.